TY  - GEN
AU  - Black,Jonathan
AU  - Menderes,Gulden
AU  - Bellone,Stefania
AU  - Schwab,Carlton L
AU  - Bonazzoli,Elena
AU  - Ferrari,Francesca
AU  - Predolini,Federica
AU  - De Haydu,Christopher
AU  - Cocco,Emiliano
AU  - Buza,Natalia
AU  - Hui,Pei
AU  - Wong,Serena
AU  - Lopez,Salvatore
AU  - Ratner,Elena
AU  - Silasi,Dan-Arin
AU  - Azodi,Masoud
AU  - Litkouhi,Babak
AU  - Schwartz,Peter E
AU  - Goedings,Peter
AU  - Beusker,Patrick H
AU  - van der Lee,Miranda M C
AU  - Timmers,C Marco
AU  - Dokter,Wim H A
AU  - Santin,Alessandro D
TI  - SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
SN  - 1538-8514
PY  - 2017///0629
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Animals
KW  - Antibody-Dependent Cell Cytotoxicity
KW  - immunology
KW  - Antineoplastic Agents
KW  - chemistry
KW  - Bystander Effect
KW  - Cathepsin B
KW  - genetics
KW  - Cell Line, Tumor
KW  - Cell Survival
KW  - drug effects
KW  - Class I Phosphatidylinositol 3-Kinases
KW  - Cystadenocarcinoma, Serous
KW  - drug therapy
KW  - Disease Models, Animal
KW  - Duocarmycins
KW  - Female
KW  - Gene Expression
KW  - Humans
KW  - Immunoconjugates
KW  - Indoles
KW  - Mice
KW  - Middle Aged
KW  - Mutation
KW  - Phosphatidylinositol 3-Kinases
KW  - Pyrrolidinones
KW  - Receptor, ErbB-2
KW  - antagonists & inhibitors
KW  - Survival Analysis
KW  - Uterine Neoplasms
KW  - Xenograft Model Antitumor Assays
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.1158/1535-7163.MCT-16-0163
ER  -